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Distribution and functional role of renal ET receptor subtypes in
normotensive and hypertensive rats. Experiments were designed to
compare the distribution and physiological roles of endothelin (ET)
receptor subtypes, ETA and ETB, in the kidneys of normotensive Srague
Dawley (SD) and spontaneously hypertensive (SH) rats. Using [12 I] ET-1
and subtype-selective ligands sarafotoxin 6c (S6c, ETB-selective agonist)
and BQ123 (ETA-selective antagonist), the distribution of ETA and ET
receptors in SD rat kidney cortex, outer medulla and papilla was calcu-
lated to be 50:50, 30:70 and 10:90, respectively. The ET receptor subtypes
in outer medulla and papilla of age-matched SH rats were similar to those
of SD. However, in the cortex of SH rats, the ratio of ETA to ET8 was
25:75 compared to 50:50 in SD rats. In addition, the affinity of the ET
receptors was also higher in SH rats (117 M vs. 235 pM). In the conscious
SD rats, bolus i,v. injections of ET-1 and S6c elicited similar dose-
dependent decrease in renal blood flow (RBF), which were unaffected by
the infusion of the selective ETA receptor antagonist, BQ123. The SH rats
were more sensitive to the renal vasoconstrictor effect of S6c and ET-1.
Also, the dose-response curve to S6c was shifted to the left when
compared to ET-1; however, BQ123 infusion abolished this difference. In
renal clearance studies, BQ123 infusions decreased RBF and glomerular
filtration rate (GFR) only in SH rats, and the fractional excretion of
sodium only in SD rats. The combined data indicate that the distribution
and functional roles of ETA and ET receptor subtypes are altered in the
kidneys of SH rats.
The isolation of endothelin (ET-1), a 21-amino acid peptide
from endothelial cells by Yanagisawa et al [1] soon was followed
by the discovery of two related peptides, ET-2 and ET-3, and the
family of sarafotoxins (SX) that show high degrees of homology to
ET-1 [2]. It is now well established that ET is distributed in a large
variety of organs and tissues, including the kidney [reviewed in 3,
4]. The various physiological responses to ET are mediated by its
interaction with specific cell surface receptors of the target tissues.
To date, two different ET receptor subtypes have been cloned and
sequenced: the ETA subtype from bovine lung [5] and the ETB
subtype from rat lung [6]. The ETA receptor is selective for ET-1,
whereas ET8 receptor binds with equal affinity to ET and SX
peptides [7]. Of the sarafotoxins, S6c alone binds only to the ETB
receptor with high affinity [8]. Recently, a cyclic pentapeptide
(BQ123) has been described [9] that shows high selectivity for the
ETA receptor.
Evidence on the physiological roles of the two ET receptor
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subtypes is emerging slowly, and is often controversial. It is now
clear that both ETA and ETB receptors mediate smooth muscle
contraction, albeit in different tissues [10, 11]. The ETB receptor
also has been shown to mediate release of nitric oxide (NO) in
various cells [12, 13]. Both receptors are found in the mammalian
kidney, although their distribution differs between species [14, 15].
An abundance of evidence has emerged recently showing that, in
the rat, renal vasoconstriction is mediated by the ETB receptor
[16, 17]. This is despite earlier observations from mRNA mea-
surements [18] and radioligand binding studies [19] that ETA
receptors are located primarily on vascular smooth muscle cells
and ETB receptors on tubular epithelial cells. In addition, ETB
receptor was shown to mediate ET-induced increase in glomeru-
lar cGMP [20] and inhibition of AVP-stimulated cAMP in IMCD
cells by ET [21]. A recent report by us [22] would indicate that a
critical role of the ETA receptor in the rat kidney is that of
inhibiting tubular absorption of sodium.
To date, most studies on the ET receptor subtypes have been
performed in normotensive animals. Our studies were designed to
compare the distribution of the two receptor subtypes and their
role in the control of renal function between normotensive and
spontaneously hypertensive rats. Pharmacologic tools included
ET-1 (nonselective agonist), S6c (ETB selective agonist) and
BQ123 (ETA selective antagonist). The whole animal studies were
performed in conscious, chronically instrumented rats, completely
recovered from surgery. Three experimental approaches were
used: (1) in vitro radioligand studies on membranes prepared from
various regions of the kidney; (2) renal vasoconstrictor dose-
response studies with ET-1 and S6c in conscious SD and SH rats,
in the presence and absence of the ETA receptor antagonist,
BQ123; and (3) renal clearance studies with BQ123 to elucidate
the physiological role of the renal ETA receptor under endoge-
nous activation.
Methods
Fully grown (13 to 16 week) male Sprague-Dawley (SD) and
Okamoto strain spontaneously hypertensive (SH) rats were ob-
tained from Charles River Labs (Wilmington, Massachusetts,
USA). All procedures were approved by the Institutional Animal
Care and Use Committee and were in accordance with National
Institute Guidelines for the care and use of animals.
In vitro studies
Membrane preparation. Whole kidneys were removed from
anesthetized rats and the cortex, medulla and papilla were
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dissected out. The tissues were homogenized (1 g!10 ml) in 20 mM
Tris HC1, pH 7.4, 5 mM EDTA, 0.25 M sucrose, 100 sg/ml
phenylmethyl sulfonyl fluoride, 10 pg/ml aprotinin and 10 g/ml
leupeptin (Buffer A), using a tissue homogenizer (15 strokes). The
homogenate was centrifuged for 15 minutes at 4°C at 1000 X g.
The supernatants were decanted, filtered through cheesecloth and
centrifuged for 30 minutes at 4°C at 40,000 X g. The resulting
pellets were resuspended in Buffer B (50 mivi Tris HC1, pH 7.5 and
20 mM MgC12).
[1251] ET-1 binding. [125!] ET-1 binding to membranes prepared
from various regions of rat kidney was performed in buffer
containing 50 mM Tris HC1, pH 7.5, 10 mM MgC12 and 0.05%
bovine serum albumin as described [14]. [1251] ET-1 (0.2 to 0.3 nM)
was added to tubes containing membranes (5 to 6 pg/tube) for
cortex, 3 to 4 j.Lg/tube for medulla and 1 to 2 sg/tube for papilla)
and incubated for 60 minutes at 30°C. Nonspecific binding was
determined in the presence of 1 tM unlabeled ET-1. The reac-
tions were terminated with 3 ml cold buffer containing 50 mri Tris
HC1, pH 7.5 and 10 mi MgC12. Bound and free ligands were
separated by filtering the incubation mixture through a Whatman
GF/C filter paper presoaked in 0.1% bovine albumin serum using
a Brandel cell harvester. Saturation binding experiments were
performed using increasing concentrations of [1251] ET-1 (10 pM
to 600 pM) in the absence or presence of 1 M unlabeled ET-1.
Competition binding experiments were performed using 0.2 to 0.3
nM [I] ET-1 in the absence and presence of increasing concen-
trations of unlabeled ligands. Each experiment was performed two
to three times from membranes prepared from five to six Sprague-
Dawley (SD) or spontaneously hypertensive (SH) rats. The data
presented are from representative experiments.
In vivo studies
Animal preparation. The surgical preparation, pre- and post-
surgical care, and the experimental set-ups have been previously
described [23]. Briefly, under ketamine hydrochloride (60 mg/kg,
i.m.) and sodium pentobarbital (20 mg/kg, i.p.) anesthesia, the rats
were prepared either for measurement of systemic and renal
hemodynamic parameters or for renal clearance studies. Medical-
grade Tygon catheters were implanted in the abdominal aorta and
vena cava of all rats. In addition, a pulsed Doppler flow probe was
placed around the left renal artery. All tubings and lead wires of
the probes were tunneled under the skin and exited in the
midscapular region. When not in use, the catheters were filled
with a 1:1 mixture of 50% dextrose and heparin (1000 U/mI) and
sealed under pressure with stainless steel pins. A silastic-covered
stainless steel cannula was also sewn in the urinary bladder of rats
prepared for renal clearance studies. All rats were accustomed to
a plastic restrainer (Model ECU, Braintree Scientific, Inc., Brain-
tree, Massachusetts, USA) prior to surgery and during 6 to 10
days of recovery period. They were housed individually after
surgery and had continuous access to food (Formula 500, Ralston
Purina Co., St. Louis, Missouri, USA) and water until the day of
the experiment.
Experimental groups
Dose-response studies with ET-1 and S6c. Rats were weighed,
placed in the restrainer, and connections were made for the
monitoring of arterial pressure via a Gould transducer, renal
blood flow via a Doppler flow meter (Model DM-1, Crystal
Biotech, Holliston, Massachusetts, USA), and for intravenous
administration of vehicle and test compounds. The hemodynamic
parameters were recorded on a Gilson polygraph (Model 5/6H,
Gilson Co., Middleton, Wisconsin, USA). After a 60-minute
equilibration period, a bolus injection of vehicle (0.05% BSA in
5% dextrose) was given via the implanted venous catheter. This
was followed by bolus injections of 0.01, 0.03, 0.1, and 1 nm/kg
ET-1 or S6c at three to four minute intervals in volumes of 0.5
mI/kg. The experiments were repeated in the same rats on
different days during the infusion of BQ123. The ETA receptor
antagonist was infused at a rate of 100 kg min' during
the whole experimental period. In preliminary studies, this dose of
BQ123 effectively (—50%) blocked the pressor response to a
maximum dose of ET-1. Four experiments (ET-1; BQ123 and
ET-1; S6c; and BQ123 and S6c) were performed in each of six SH
and five SD rats. The procedures were randomized, with at least
two days allowed for recovery between experiments.
Renal clearance studies with BQ123. These experiments were
also performed in SH (N = 6) and SD (N = 5) rats. They were set
up as described above for the continuous recording of blood
pressure. To facilitate collection of urine, the bladder cannula was
extended with a silastic tubing with a total dead space of <50 i'l.
Throughout the experiment, isotonic saline containing 10% inulin
(Iso-Tex Diagnostics, Friendswood, Texas, USA) and 1% p-
aminohippurate (PAH; Merck, Sharp and Dohme, West Point,
Pennsylvania, USA) was infused i.v. at a rate of 20 j.dlmin. The
vehicle for BQ123 was also infused i.v. at a pump rate of 10
.d/min. One hour equilibration was followed by two 30-minute
urine collections (control). Then, vehicle infusion was replaced by
BQ123 at a rate of 100 pg/kg mm. Urine collection was resumed
in 30 minutes and two additional collections were performed. A
blood sample (300 p1) was drawn via the aortic catheter at the
midpoint of each collection period. The plasma was separated, the
cells resuspended in sterile saline and returned to the rat.
Analyses
Urinary and plasma concentrations of inulin were determined
by the anthrone method [24], and those of PAH by the method of
Smith et a! [25]. Electrolyte concentrations were measured using
a Synchroin ASS clinical analyzer, osmolality by an automatic
osmometer (Model 2430, Precision Systems, Inc., Natick, Massa-
chusetts, USA). Renal clearance values were calculated using
standard clearance formulae and expressed per 100 g body weight.
The values for the dose-response curves are expressed as
percent changes from baseline values and are reported through-
out as group means SEM. The effective doses of ET-1 and S6c
that would elicit an increase of 20% (ED20) in MAP or a decrease
of 50% (ED50) in RBF were calculated from the dose-response
curves for each rat from linear-regression analysis. As each rat was
exposed to four different procedures, the curve parameters were
compared using an analysis of variance for repeated measures.
Post-hoc comparisons were made with the Duncan's multiple-
range test. Statistical analysis of the renal clearance data was
performed by analysis of variance and a subsequent Student's
t-test. A value of P < 0.05 was considered statistically significant.
Drugs and solutions
ET-1 and sarafotoxin S6c were from Sigma Chemical Co. (St.
Louis, Missouri, USA). 103M aliquots were frozen at —70°C,
diluted on the day of the experiment in 5% dextrose with 0.05%
BSA. BQ123 was synthesized at SmithKline Beecham (King of
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Prussia, Pennsylvania, USA), dissolved daily in 5% dextrose
containing 0.05% Na2CO5.
Results
In vitro studies
The density and proportion of ETA and ET receptors in
different regions of SD and SH rat kidneys were quantified by
performing saturation binding experiments using [12511 ET-1 in
the absence and presence of the ETA-selective antagonist, BQ123
to quantitate total (ETA and ETC) and ET receptors, respec-
tively. The binding of [12511 ET-1 to membranes prepared from
SD and SH rat kidney cortex, medulla and papilla was specific and
saturable. Scatchard transformation of the specific binding from
saturation binding experiments displayed a single class of high
affinity binding as shown in Figure 1. The apparent dissociation
constants, maximum binding and the proportion of ETA and ET8
receptors for all three regions in SD and SH rats are presented in
Table 1. In outer medulla, the ratio of ETA and ET receptors was
30:70 (Fig. 1 C, D) and in papilla (Fig. 1 E, F) > 90% of the ET
Fig. 1. Scatchard analysis of the specific
binding obtained from saturation binding
experiments in SD and SH rat kidney cortex
(A and B), medulla (C and D) and papilla
(E and F). Increasing concentrations of
[1251] ET-1 in the absence (0) or presence(•) of 1 jkM B0123 were added to the
membrane fractions and incubated for 60
mm at 30°C. Bound and free ligands were
separated as explained in the Methods.
The data shown are from one experiment
which is representative of 3 to 4
experiments.
receptors belonged to the ET subtype in SD and SH rats, In
contrast, the distribution of ETA and ETB receptors in the cortex
of SD and SH rats was 50:50 and 25:75, respectively, indicating a
higher proportion of ET receptors (Fig. 1 A, B, Table 1). Since
the total number of receptors did not change significantly between
SD and SH rats, the increase in the proportion of ET receptors
was accompanied by a concomitant decrease in the proportion of
ETA receptors (Table 1). In addition, the ET receptors present in
SH rat kidney cortex displayed higher affinity when compared to
SD rat kidney cortex (117 10 vs. 235 57 pM). The relative
distribution as well as the changes in ETA and ETB receptor
subtypes in SH rat kidney cortex were further confirmed by
performing competition binding experiments using ['I] ET-1
and subtype-selective ligands 56c (ET8-selective) and BQ123
(ETA-selective). In the SD rat kidney cortex, the ET-1 displace-
ment curve was monophasic, whereas ET-3 and S6c displayed
biphasic competition curves, indicating more than one subtype of
ET receptor. Furthermore, BQ123 was unable to displace 50% of
[12511 ET-1 binding, even at 1 jiM, indicating that 50% of ET
0
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Table 1. Distribution of ETA and ETh receptors in SD and SH rat kidneys
SD SH
Tissue Bma, % ETB Bmn K.4 % ETB
Cortex
[125j] FT-i 251 58 235 57 284 13 117 10['I] FT-i + B0123 121 19 214 48 48 211 15 113 10 72
Medulla
['I] FT-i 388 19 146 43 417 16 142 31
[125!] ET-1 + B0123 270 11 132 36 70 271 22 116 29 65
Papilla['1] FT-i 2020 144 75 17 2077 212 53 3
['I] FT-i + BQ123 1964 146 67 4 97 1923 119 56 5 93
The data are calculated from saturation binding of [1I] FT-i to various membrane fractions. Binding of [1I] FT-i to the membrane fractions in
the absence of BQ123 (1 saM) represents the total density of ETA and FT11 receptors. in the presence of BQ123, the binding of [1f] FT-i represents
FT11 receptors. Bm is represented as fmol/mg protein and K.1 is represented as pM.
Table 2. Baseline values of mean arterial pressure and renal blood flow
for each protocol
SD(N= 5) SH(N
MAP
= 6)
RBFMAP RBF
mm Hg kHz mm Hg kHz
Vehicle + FT-i 107 1 10.6 2.4 178 5 7.8 1.6
BQ123 + FT-i 101 4 9.5 i.3 16i 4 7,2 2.3
Vehicle + S6c 105 3 103 1.3 183 6 8.0 1.5
BQ123 + S6c 102 3 10.1 1.4 i65 V 7.1 1.0
The values represent means SEM of readings taken at the end of
equilibration period, preceding the dose-response procedures with FT-i
or S6c.
a Significantly different from "vehicle" group
receptors belong to FT11. When similar experiments were per-
formed using SH rat kidney cortex, it was observed that BQ123
displayed only 30% of [125!] FT-i binding, indicating that 70% of
the ET receptors belong to FT11 subtype. This was supported by
the binding profile of ET-3 and S6c. There was no significant
differences in the binding characteristics of FT-i, ET-3, S6c or
BQ123 between SD and SH rat kidney medulla or papilla.
In vivo studies
Dose-response studies with ET-1 and Sóc. Baseline values for
MAP and RBF recorded during the four protocols (in the same
rats on separate days) are presented in Table 2. For the SD rats,
no significant differences between values on the four test days
were noted. In the SF1 rats, however, BQ123 infusion significantly
decreased basal blood pressure. Representative tracings of hemo-
dynamic responses to cumulative doses of S6c are presented in
Figure 2 from experiments in SD and SF1 rats. Dose-dependent
increases in MAP and decreases in RBF were elicited in the SD
rat by the FT11 agonist. The decrease in RBF was also dose-
dependent in the SHR. A small hypotensive effect preceded the
increase in blood pressure at higher doses of S6c (0.1 and 0.3
nm/kg) in the SD rats; this effect was exaggerated both in
magnitude and duration in the SH rats. Neither FT-i nor 56c
increased MAP significantly in the SH rats with the protocol used.
Figure 3 illustrates the effect of B0123 on the cumulative FT-i
and S6c-induced increase in MAP in SD rats. FT-i administration
caused a dose-dependent increase in MAP, reaching a maximum
of 46 4% at a dose of 0.3 nm/kg and an ED20 of 0.024 .01
nm/kg (Fig. 3A). Infusion of BQ123 shifted the FT-i pressor
dose-response curve to the right by 15-fold (ED20 = 0.37 0.04
nm/kg); however, BQ123 infusion had no measurable effect on the
pressor dose-response to S6c (Fig. 3B). Due to potent renal
vasoconstrictor effects of these peptides, we did not attempt to
obtain the maximal increase in MAP.
Dose-response curves for renal vasoconstriction obtained with
FT-i and S6c in SD rats infused with vehicle or BQ123 are
presented in Figure 4 A and B and for the SF1 rats in Figure 4 C
and D. Under control conditions, the dose of S6c that produced a
50% decrease in RBF (ED50) was significantly lower than that of
FT-i, both in the SD (0.i6 0.03 vs. 0.51 0.08 nm/kg, P < 0.05)
and in the SF1 rats (0.09 0.02 vs. 0.29 0.05 nm/kg, P < 0.05).
B0123 infusion shifted the FT-i dose-response to the left in both
strains (Figure 4 A and C); however, the shift was significant (P <
0.05) only in the SF1 rats (ED5O 0.12 0.03 vs. 0.29 0.95 nm/kg)
compared to the control group. These results indicate that renal
vasoconstriction in the rat is mediated by the FT11 receptor
subtype, and that stimulation of the ETA receptor slightly atten-
uates this response. This was further confirmed by the dose-
response curve obtained with 56c and the lack of BQ123 effect on
S6c-mediated response (Fig. 4 B, D). Thus, the dose-response
curves obtained for FT-i in the presence of B0123 were super-
imposable with those of S6c in both species. It is also evident that
activation of the El'11 receptor by S6c or by the combination of
ET-i + BQ123 elicits more potent vasoconstriction in the kidney
of SF1 than of SD rats (Fig. 5).
Renal clearance studies with BQ123. Sustained infusion of
B0123 resulted in a moderate decrease in MAP in both rat strains
(Table 3), similar to the pattern observed in the dose-response
studies (Table 2). Again, the change was statistically significant
only in the SH rats. Hematocrit also showed a tendency to
decrease in both groups (Table 3). In contrast, the effect of B0123
on renal hemodynamics were markedly different in the two
strains. Blockade of the ETA receptor subtype in the SD rats
slightly increased GFR, and had no effect on RBF or renal
vascular resistance (Fig. 6). In contrast, GFR and RBF signifi-
cantly decreased and RVR increased in the SF1 strain (Fig. 6).
Urine flow decreased significantly in both groups with BQ123, by
72% in the SD and by a smaller decrement (46%) in the SH rats.
The decrease in osmolal clearance fully accounted for the drop in
urine flow (Table 3). Excretion of sodium and potassium also
decreased significantly in both rat strains (not shown); however,
SD
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the decrease in the fractional excretion of these electrolytes was
statistically significant only in the SD rats (Table 3).
Fig. 2. Representative tracings of the effects
of bolus i.v. injections of sarafotoxin óc
(S6c, 0.01 to 0.3 nmol/kg) on mean aortic
pressure (MAP) and renal blood flow (RBF)
in conscious Sprague-Dawley (SD) and
spontaneously hypertensive (SH) rats.
Fig. 3. Effects of BQ123 on the dose-
response curves for the systemic pressor
effects of ET-1 (A) and S6c (B) in
conscious normotensive (SD) rats. Control
(0); BQ123 (100 sg/kg mm; •). Results
are expressed as means SE of %
changes from baseline. In (A), (0) ED20
= 0.024 0.01; (I) ED = 0.37
ØØ4*; in (B), (0) ED20 = 0.028 0.01;(•) ED20 = 0.53 0.02. *sjgflificafltly
different from ED20 of control group (N =
5).
receptors in medulla and papilla between SD and SH rats. In
contrast, there was a significant difference in the cortical ET
receptors between the two rat strains. While total ET-1 binding
remained similar in SD and SH rats, the proportion of ETB
receptors in the kidney cortex was significantly higher in the SH
than SD rats. In addition, there was a significant increase in the
affinity of these receptors in SH rats when compared to SD rats.
The studies we performed had two major objectives. First, to
compare the distribution of the two endothelin receptor subtypes,
ETA and ETB, in the various regions of the kidneys from
normotensive Sprague-Dawley rats with those of spontaneously
hypertensive rats and second, to examine the role of these
endothelin receptor subtypes in mediating systemic and renal These changes were further confirmed by performing competition
vasoconstriction and renal tubular function, binding experiments in the presence of subtype-selective ligands.
1' 1'
0.1 0.3
1
0.1
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0.3
I
Sarafotoxin 6c, nmol/kg, Lv.
B
50
3-
40
30
40
20
30
0
10
20
0
10
0
V 0.01 0.1 1 V 0.01 0.1 1
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Discussion
The results of our binding studies show that there was no
significant difference in the distribution and affinities of the ET
ET-1, nmol/kg, I. v.
LI
SC6, nmol/kg, i.v.
Fig. 4. Effects of BQ123 on renal
vasoconstriction in response to ET-1 and
S6c in conscious SD (A and B) and SH (C
and D) rats. In A through D, symbols are:
(0) control; (•) BQ123. In (A), (0)
ED50 = 0.51 0.08; () ED50 = 0,23
0.05; in (B), (0) ED50 = 0.16 0.03; ()
ED50 = 0.19 0.06; in (C), (0) ED50 =
0.29 0.05; (•) ED50 0.12 0.03*; in
(D), (0) ED50 = 0.09 0.02; (•) ED50
= 0.11 0.06. All values are expressed as
means SE of % changes from baseline.
*significantly different from control group.
Since it is now well established and supported by our results
that ET-induced renal vasoconstriction in the rat is mediated by
the ETB receptor subtype, the major contribution of this study is
the demonstration that the increased proportion of ETB receptors
in the kidney cortex of SH rats was accompanied by an altered
responsiveness to ET. Thus, we were able to show that there is a
good correlation between the higher density and affinity of the
ETB receptor subtype in SH rats, and the increased potency of the
selective ETB receptor agonist, S6c, in mediating renal vasocon-
striction, The evidence is less compelling regarding the role of
ETA receptor subtype. BQ123 shifted the renal ET-1 dose-
response curve to the left in both rat strains (significantly in the
SH rats), indicating an ETA receptor-induced attenuation of the
ETA-mediated renal vasoconstriction. Inasmuch as the density of
the ETA receptor subtype is decreased and that of the ET
receptor subtype is increased in the SH rat, the result could be a
net increase in ET-mediated vasoconstriction. Removal of the
ETA-mediated attenuating effect, as in our renal clearance studies
with BQ123, could further increase the ETB-mediated vascular
tone, hence the decrease in RBF and GFR. In contrast, the
contribution of renal hemodynamics in the normotensive rat
could be negligible, thus blockade of one receptor would have no
measurable effect. In agreement with an earlier report [26], we
also observed no changes in RBF and GFR with infusion of
B0123 in the normotensive rats. Taken together, the results
would indicate (do not prove) that in the SH rats, changes in the
density of ET receptor subtypes may contribute to the increased
renal vascular resistance, a primary characteristic of this rat strain
[27].
In addition to its vasoconstrictor effect, ET has been shown to
inhibit tubular reabsorption of sodium and water; however, the
evidence is scarce regarding the receptor subtype involved in this
process. The results from our renal clearance studies indicate that
ETA receptors play an important role as endogenous inhibitors of
sodium reabsorption in the normotensive rats. This role is some-
what diminished in the SH rats, a possible result of decreased ETA
receptor density in the kidney cortex. It has also been proposed
that reduced production of ET-1 in the inner medulla of SH rats
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Table 3. Response of Sprague-Dawley and SHR to a 75 minute
infusion of BQ123
V 0.01 0.1 1
SD(N= 5) SH(N= 6)
Control BQ123 Control BQ123
MAP mm Hg 115 3 108 2.5 182 4.7 163 77a
HR beats/mm 371 9 401 6 352 10 344 7
Hematocrit % 39.5 0.9 36 1.1 42 0.4 40 0.6
V p1/mm 100g 17.9 1.6 5.1 0.48 11.8 2.0 6.4 1.1
U0,,,, mOsm/kg 694 90 1382 848 725 52 1140 608
H20
GFR 961 56 1089 53 717 30 605 368
p1/mm l00g
RBF 4692 390 4464 123 4497 148 3462 2418
p1/mm 100g
FF % 33.7 1.1 38.3 3.8 27.4 1.0 30.5 2.5
1Na % 1.5 0.2 0.64 0.128 1.06 0.1 0.98 0.1
FEK % 46.7 3.8 30.6 398 38.5 4.6 31.6 5.2
CH2
pYlmin 100 g
—19.5 2.8 —18.9 0.4 —19.5 1.9 —16.9 2.7
Cosm 37.4 2.1 24.1 0.28 31.4 2,5 25.8 3.5
j.d/min 100g
B
Fig. 5. Comparison of ETB receptor
subtype-mediated renal vasoconstriction in
SD (0, N = 5) and SH (•, N = 6) rats.
(A), (0) ED50 = 0.23 0.05; (•)
v 0.01 0.1 1 ED50 = 0.12 0.03*; in (B), (0) ED50 =
0.16 0.013; () ED50 = 0.09 0.02*.
SC6 nmol/kg .v. All values are reported as means s of% change from baseline. *signiflcantly
different from SD rats.
elucidate the site of action of ETA-mediated inhibition of sodium
reabsorption and the physiologic importance of ETB-mediated
inhibition of water reabsorption.
It is important to note here that there is an emerging evidence
regarding species specificity in the function of ET receptors. A
recent report [31] shows that in the dog kidney, the roles of the
two receptor subtypes are reversed. We are also cognizant of the
lack of some critical information which would allow us to reach
more definite conclusions based on the voluminous data pre-
sented here. In addition, we have to consider some new evidence
[32] suggesting the existence of two ETB receptor subtypes: one
mediating release of nitric oxide, the other responsible for con-
traction of vascular smooth muscle in various tissues, such as the
rat kidney. Resolutions to the questions raised here will be
facilitated by the development of subtype-selective receptor ago-
fists and, more importantly, antagonists.
In summary, results of in vitro and in vivo studies showed a
significant decrease in ETA and increase in ETB receptor subtype
density in the kidney cortex of SH rats and parallel alterations in
their functional roles in the SH when compared to normotensive
SD rats. ETB receptor-mediated renal vasoconstriction was p0-
tentiated and the ETA receptor-mediated inhibition of sodium
reabsorption was attenuated in the SH rats. Results of renal
clearance experiments suggest that in the conscious normotensive
rats, ET may not play a significant role in the control of renal
hemodynamics, whereas in the hypertensive rats, changes in the
density and/or affinity of the ET receptor subtypes as well as
possible alterations in their complex post-receptor signaling path-
ways may contribute to the increase in renal vascular resistance
and to the pathogenesis of hypertension.
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The values listed under Control are the means 5EM of two clearance
periods before infusing B0123; those under BQ123 are the means SEM
of the last clearance period obtained during the 75 mm infusion of BQ123.
Abbreviations are: MAP, mean arterial pressure; HR, heart rate; V, urine
flow; Uosm, urine osmolality; GFR, glomerular filtration rate; RBF, renal
blood flow; FF, filtration fraction; FEN8, fractional excretion of Na; FEK,
fractional excretion of K; CH20, clearance of free water; Cosm, clearance
of osmoles.
a Significantly different from control, P < 0.05
may contribute to its impaired effectiveness as a natriuretic factor
[28]. However, ETB receptors predominate in the inner medullary
segment of the nephron in the rat kidney, and it is this receptor
subtype that mediates ET inhibition of vasopressin-induced water
reabsorption [21]. Recently emerging evidence indicates that ET
also plays an important role in proximal tubular transfer of
Na-K-ATPase and Na/PO4 exchange [291. An earlier report
by Harris and associates [30] also showed that infusion of low dose
of endothelin induced natriuresis by inhibiting Na reabsorption
mostly in the proximal tubule. Thus, further studies are needed to
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Fig. 6. Effect of ETA receptor subtype
blockade with BQ123 on renal
hemodynamics in conscious SD (U, N = 5)
and SH (. N = 6) rats. Abbreviations
are: GFR, glomerular filtration rate; RBF,
renal blood flow; RVR, renal vascular
resistance. Values are expressed as means
SE of % changes for GFR and REF and
as absolute values for RVR. Control (solid
bars); BQ123 (100 sg/kg mm; striped
bars). Significantly different from control.
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